<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39371289</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>08</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">1679-4435</ISSN><JournalIssue CitedMedium="Print"><Volume>22</Volume><Issue>2</Issue><PubDate><Year>2024</Year><Season>Apr-Jun</Season></PubDate></JournalIssue><Title>Revista brasileira de medicina do trabalho : publicacao oficial da Associacao Nacional de Medicina do Trabalho-ANAMT</Title><ISOAbbreviation>Rev Bras Med Trab</ISOAbbreviation></Journal><ArticleTitle>Waning immune response to CoronaVac in health care workers from different age groups.</ArticleTitle><Pagination><StartPage>e20221048</StartPage><MedlinePgn>e20221048</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e20221048</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.47626/1679-4435-2022-1048</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="UNASSIGNED">The waning of serum antibodies against severe acute respiratory syndrome coronavirus 2 observed in several studies raises questions about long-term immunity. Lower antibody levels are associated with new cases of COVID-19 even postvaccination, leading to the administration of booster doses.</AbstractText><AbstractText Label="OBJECTIVES" NlmCategory="UNASSIGNED">To evaluate the postvaccination immune humoral response and the relationship between postvaccination seropositivity rates and demographic data among health care workers 6 months after CoronaVac vaccination.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">This was a cross-sectional study including health care workers vaccinated with two doses of CoronaVac after 6 months or more. The present study was conducted with the analysis of postvaccination serology test to assess the level of humoral response (anti-receptor binding domain IgG) after vaccination.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">A total of 325 participants were enrolled, of whom 76% were female, with a median age of 42 years (20-85; interquartile range 31-53). Overall, 18.8% (61) of the participants results were seropositive for anti-receptor binding domain IgG; 81.2% did not have sufficient quantitative titers. The IgG titers obtained from female health care workers did not differ from those obtained from seropositive male health care workers, regardless of age.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">A group of positive quantitative titers was identified in the serology test for IgG antibodies against severe acute respiratory syndrome coronavirus 2. Further studies are needed to determine the durability of postvaccination antibodies and how serology testing can be used to determine the ideal timing for booster doses of the vaccine.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Taminato</LastName><ForeName>Monica</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-4075-2496</Identifier><AffiliationInfo><Affiliation>Medicina, Universidade Federal de São Paulo, São Paulo, SP, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chaves</LastName><ForeName>Ana Paula</ForeName><Initials>AP</Initials><Identifier Source="ORCID">0000-0003-0321-6977</Identifier><AffiliationInfo><Affiliation>Medicina, Universidade Federal de São Paulo, São Paulo, SP, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Morais</LastName><ForeName>Richarlisson</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0003-0009-1750</Identifier><AffiliationInfo><Affiliation>Medicina, Universidade Federal de São Paulo, São Paulo, SP, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Conte</LastName><ForeName>Danielle</ForeName><Initials>D</Initials><Identifier Source="ORCID">0000-0002-4351-0831</Identifier><AffiliationInfo><Affiliation>Medicina, Universidade Federal de São Paulo, São Paulo, SP, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gabrielloni</LastName><ForeName>Maria Cristina</ForeName><Initials>MC</Initials><Identifier Source="ORCID">0000-0003-2395-9161</Identifier><AffiliationInfo><Affiliation>Medicina, Universidade Federal de São Paulo, São Paulo, SP, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Barbosa</LastName><ForeName>Gabriela</ForeName><Initials>G</Initials><Identifier Source="ORCID">0000-0002-3386-8581</Identifier><AffiliationInfo><Affiliation>Medicina, Universidade Federal de São Paulo, São Paulo, SP, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Medeiros</LastName><ForeName>Eduardo</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-6205-259X</Identifier><AffiliationInfo><Affiliation>Medicina, Universidade Federal de São Paulo, São Paulo, SP, Brazil.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bellei</LastName><ForeName>Nancy</ForeName><Initials>N</Initials><Identifier Source="ORCID">0000-0001-6080-5693</Identifier><AffiliationInfo><Affiliation>Medicina, Universidade Federal de São Paulo, São Paulo, SP, Brazil.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>24</Day></ArticleDate></Article><MedlineJournalInfo><Country>Brazil</Country><MedlineTA>Rev Bras Med Trab</MedlineTA><NlmUniqueID>101214718</NlmUniqueID><ISSNLinking>1679-4435</ISSNLinking></MedlineJournalInfo><OtherAbstract Type="Publisher" Language="por"><AbstractText Label="INTRODUÇÃO" NlmCategory="UNASSIGNED">O declínio dos anticorpos séricos contra a síndrome respiratória aguda grave do coronavirus 2 observado em vários estudos levanta questões sobre a imunidade a longo prazo. Níveis mais baixos de anticorpos estão associados a novos casos de covid-19 mesmo após a vacinação, levando à administração de doses de reforço.</AbstractText><AbstractText Label="OBJETIVOS" NlmCategory="UNASSIGNED">Avaliar a resposta imunitária humoral após a vacinação e a relação entre as taxas de soropositividade após a vacinação e dados demográficos em trabalhadores da saúde por mais de 6 meses após a imunização com CoronaVac.</AbstractText><AbstractText Label="MÉTODOS" NlmCategory="UNASSIGNED">Estudo transversal incluindo profissionais de saúde vacinados com duas doses de CoronaVac após 6 meses ou mais. O estudo foi realizado com a análise do teste sorológico após a vacinação para avaliar os níveis de resposta humoral (anti-domínio de ligação ao receptor IgG) após a vacinação.</AbstractText><AbstractText Label="RESULTADOS" NlmCategory="UNASSIGNED">Neste estudo foram incluídos 325 participantes, 76% do sexo feminino e a idade mediana foi de 42 anos (20-85; intervalo interquartil 31-53). No geral, 18,8% (61) dos resultados dos participantes foram soropositivos para IgG anti-domínio de ligação ao receptor; 81,2% não apresentaram títulos quantitativos suficientes. Os títulos de IgG obtidos para os profissionais de saúde do sexo feminino não foram diferentes daqueles obtidos para os participantes do sexo masculino com soropositividade, independentemente da idade.</AbstractText><AbstractText Label="CONCLUSÕES" NlmCategory="UNASSIGNED">Foi possível identificar um grupo com títulos quantitativos positivos no teste sorológico para anticorpo IgG contra a síndrome respiratória aguda grave do coronavírus 2. Mais investigações são necessárias para determinar a durabilidade dos anticorpos após a vacinação e como os testes sorológicos podem determinar o momento ideal das doses de reforço da vacina.</AbstractText></OtherAbstract><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19 serological testing</Keyword><Keyword MajorTopicYN="N">COVID-19 vaccines</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">antibodies</Keyword><Keyword MajorTopicYN="N">healthcare workers</Keyword></KeywordList><CoiStatement>Conflicts of interest: None</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>6</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>10</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>7</Day><Hour>11</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>7</Day><Hour>11</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>7</Day><Hour>5</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>9</Month><Day>24</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39371289</ArticleId><ArticleId IdType="pmc">PMC11452123</ArticleId><ArticleId IdType="doi">10.47626/1679-4435-2022-1048</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization  . WHO COVID-19 Dashboard. Geneva: WHO; 2021.  [2021 Nov. 15].  Available from:  https://covid19.who.int.</Citation></Reference><Reference><Citation>Souza WM, Buss LF, Candido DS, Carrera JP, Li S, Zarebeski AE, et al. Epidemiological and clinical characteristics of the COVID-19 epidemic in Brazil. Nat Hum Behav. 2020;4(8):856–865.</Citation><ArticleIdList><ArticleId IdType="pubmed">32737472</ArticleId></ArticleIdList></Reference><Reference><Citation>Sant’Ana G, Imoto AM, Amorim FF, Taminato M, Peccin MS, Santana LA, et al. Infection and death in healthcare workers due to COVID-19: a systematic review. Acta Paul Enferm. 2020;33:1–9.</Citation></Reference><Reference><Citation>World Health Organization  . COVAX Global Supply Forecast. Geneva: WHO; 2021.  [2021 Nov. 20].  Available from:  https://www.gavi.org/sites/default/files/covid/covax/COVAX-Supply-Forecast.pdf.</Citation></Reference><Reference><Citation>Jara A, Undurraga EA, Gonzalez C, Paredes F, Fontecilla T, Jara G, et al. Effectiveness of an inactivated SARS-CoV-2 vaccine in Chile. N Engl J Med. 2021;385(10):875–884.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8279092</ArticleId><ArticleId IdType="pubmed">34233097</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranzani O, Hitchings M, Dorion M, D’Agostini TL, Paula RC, Paula OFP, et al. Effectiveness of the CoronaVac vaccine in the elderly population during a P.1 variant associated epidemic of COVID-19 in Brazil: test-negative case control study. BMJ. 2021;374:n2015–n2015.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8377801</ArticleId><ArticleId IdType="pubmed">34417194</ArticleId></ArticleIdList></Reference><Reference><Citation>Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021;27(7):1205–1211.</Citation><ArticleIdList><ArticleId IdType="pubmed">34002089</ArticleId></ArticleIdList></Reference><Reference><Citation>Bergwerk M, Gonen T, Lustig Y, Amit S, Lipsitch M, Cohen C, et al. Covid-19 breakthrough infections in vaccinated health care workers. N Engl J Med. 2021;385(16):1474–1484.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8362591</ArticleId><ArticleId IdType="pubmed">34320281</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng S, Phillips DJ, White T, Sayal H, Aley PK, Bibi S, et al. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. Nat Med. 2021;27(11):2032–2040.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8604724</ArticleId><ArticleId IdType="pubmed">34588689</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y, Zeng G, Pan H, Li C, Hu Y, Chu K, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021;21(2):181–192.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7832443</ArticleId><ArticleId IdType="pubmed">33217362</ArticleId></ArticleIdList></Reference><Reference><Citation>Cromer D, Steain M, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. Neutralising antibody titres as predictors of protection against SARS-CoV-2 variants and the impact of boosting: a metaanalysis. Lancet Microbe. 2022;3(1):e52–e61.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8592563</ArticleId><ArticleId IdType="pubmed">34806056</ArticleId></ArticleIdList></Reference><Reference><Citation>Gilbert PB, Montefiori CD, Mcdermontt AB, Fong Y, Benkeser D, Deng W, et al. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial. Science. 2022;375(6576):43–50.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9017870</ArticleId><ArticleId IdType="pubmed">34812653</ArticleId></ArticleIdList></Reference><Reference><Citation>Palacios R, Batista AP, Albuquerque CSN, Patiño EG, Santos JP, Conde MTRP, et al. Efficacy and safety of a COVID-19 inactivated vaccine in healthcare professionals in Brazil: the PROFISCOV study. SSRN J. 2021</Citation></Reference><Reference><Citation>Zeng G, Wu Q, Pan H, Li M, Yang J, Wang L, et al. Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials. Lancet Infect Dis. 2022;22(4):483–495.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8651254</ArticleId><ArticleId IdType="pubmed">34890537</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>